ArticleACS omega2022
Plasmonic-Based Biosensor for the Early Diagnosis of Prostate Cancer.
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- AI-Assisted Surface-Enhanced Raman Spectroscopy for Cardiovascular Diagnostics: From Plasmonic Materials to Clinical Translation.Nanomaterials (Basel, Switzerland) · 2026Review
- Microfluidic Liquid Biopsy Minimally Invasive Cancer Diagnosis by Nano-Plasmonic Label-Free Detection of Extracellular Vesicles: Review.International journal of molecular sciences · 2025Review
- Breaking barriers in cancer diagnosis: unveiling the 4Ms of biosensors.RSC advances · 2025Review
- Plasmonic Biosensors in Cancer-Associated miRNA Detection.Biosensors · 2025Review
- Papain-Catalyzed Hydrolysis ofACS omega · 2025Article
- Plasmonic nanoparticle sensors: current progress, challenges, and future prospects.Nanoscale horizons · 2024Review
- A Highly Flexible Piezoelectric Ultrasonic Sensor for Wearable Bone Density Testing.Micromachines · 2023Article
- Ultrasensitive tapered optical fiber refractive index glucose sensor.Scientific reports · 2023Article
- Recent Trends in SERS-Based Plasmonic Sensors for Disease Diagnostics, Biomolecules Detection, and Machine Learning Techniques.Biosensors · 2023Review
- Advanced technologies for molecular diagnosis of cancer: State of pre-clinical tumor-derived exosome liquid biopsies.Materials today. Bio · 2023Article
- Device Processing Challenges for Miniaturized Sensing Systems Targeting Biological Fluids.Biomedical materials & devices (New York, N.Y.) · 2022Review
- Label-free optical biosensors in the pandemic era.Nanophotonics (Berlin, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A tapered optical fiber (TOF) plasmonic biosensor was fabricated and used for the sensitive detection of a panel of microRNAs (miRNAs) in human serum obtained from noncancer and prostate cancer (PCa) patients. Oncogenic and tumor suppressor miRNAs
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.